Literature DB >> 1654199

Resting energy expenditure in patients with non-small cell lung cancer.

E W Fredrix1, E F Wouters, P B Soeters, A C van der Aalst, A D Kester, M F von Meyenfeldt, W H Saris.   

Abstract

Resting energy expenditure (REE) was determined in 30 patients with newly detected non-small cell lung cancer. Measured values were compared with the values predicted by the Harris-Benedict (HB) formula. Mean REE was 20% higher than predicted. Sixty percent of the patients (18 patients) had an elevated REE (greater than or equal to 115%) compared with this formula. The prevalence of hypermetabolism in a group of patients with gastric and colorectal cancer was only 13% (13 of 104 patients). When corrected for fat-free mass (FFM), REE was still significantly higher (P less than 0.001) in the lung cancer group compared with the gastric and colorectal cancer group. Whereas weight loss in healthy men leads to an adaptational decrease in energy expenditure (EE), weight loss in the patients with lung cancer was accompanied by an increase in REE. Tumor stage, tumor localization, pulmonary function, or smoking behavior could not explain the observed increase in REE in patients with lung cancer. Therefore, these metabolic alterations appear to be tumor mediated.

Entities:  

Mesh:

Year:  1991        PMID: 1654199     DOI: 10.1002/1097-0142(19911001)68:7<1616::aid-cncr2820680725>3.0.co;2-3

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  9 in total

Review 1.  Models of accelerated sarcopenia: critical pieces for solving the puzzle of age-related muscle atrophy.

Authors:  Thomas W Buford; Stephen D Anton; Andrew R Judge; Emanuele Marzetti; Stephanie E Wohlgemuth; Christy S Carter; Christiaan Leeuwenburgh; Marco Pahor; Todd M Manini
Journal:  Ageing Res Rev       Date:  2010-05-14       Impact factor: 10.895

2.  Metabolism in patients with small cell lung carcinoma compared with patients with non-small cell lung carcinoma and healthy controls.

Authors:  A J Staal-van den Brekel; A M Schols; M A Dentener; G P ten Velde; W A Buurman; E F Wouters
Journal:  Thorax       Date:  1997-04       Impact factor: 9.139

3.  Cytokines, the acute-phase response, and resting energy expenditure in cachectic patients with pancreatic cancer.

Authors:  J S Falconer; K C Fearon; C E Plester; J A Ross; D C Carter
Journal:  Ann Surg       Date:  1994-04       Impact factor: 12.969

4.  The effects of treatment with chemotherapy on energy metabolism and inflammatory mediators in small-cell lung carcinoma.

Authors:  A J Staal-van den Brekel; A M Schols; M A Dentener; G P ten Velde; W A Buurman; E F Wouters
Journal:  Br J Cancer       Date:  1997       Impact factor: 7.640

5.  Proportional weight loss in six months as a risk factor for mortality in stage IV non-small cell lung cancer.

Authors:  Guilherme Watte; Claudia Helena de Abreu Nunes; Luzielio Alves Sidney-Filho; Matheus Zanon; Stephan Philip Leonhardt Altmayer; Gabriel Sartori Pacini; Marcelo Barros; Ana Luiza Schneider Moreira; Rafael José Vargas Alves; Alice de Medeiros Zelmanowicz; Bashir Mnene Matata; Jose da Silva Moreira
Journal:  J Bras Pneumol       Date:  2018 Nov-Dec       Impact factor: 2.624

6.  Reduced total energy expenditure and physical activity in cachectic patients with pancreatic cancer can be modulated by an energy and protein dense oral supplement enriched with n-3 fatty acids.

Authors:  A W G Moses; C Slater; T Preston; M D Barber; K C H Fearon
Journal:  Br J Cancer       Date:  2004-03-08       Impact factor: 7.640

7.  Do patients with weight loss have a worse outcome when undergoing chemotherapy for lung cancers?

Authors:  P J Ross; S Ashley; A Norton; K Priest; J S Waters; T Eisen; I E Smith; M E R O'Brien
Journal:  Br J Cancer       Date:  2004-05-17       Impact factor: 7.640

Review 8.  Classical experiments in whole-body metabolism: open-circuit respirometry-diluted flow chamber, hood, or facemask systems.

Authors:  P F M Schoffelen; G Plasqui
Journal:  Eur J Appl Physiol       Date:  2017-10-27       Impact factor: 3.078

9.  Neutral evolution of drug resistant colorectal cancer cell populations is independent of their KRAS status.

Authors:  Krastan B Blagoev; Julia Wilkerson; Mauricio Burotto; Chul Kim; Edward Espinal-Domínguez; Pilar García-Alfonso; Meghna Alimchandani; Markku Miettinen; Montserrat Blanco-Codesido; Tito Fojo
Journal:  PLoS One       Date:  2017-10-05       Impact factor: 3.240

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.